News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (335 of 388). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (15 of 388). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (38 of 388). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 278 of 388 items have one.
Christchurch mutation points to potential gene therapy avenue for Parkinson's
A rare genetic mutation may protect against developing Parkinson's disease and Lewy body dementia, a new study from researchers at Oregon Health & Science University suggests.
Read at Medical Xpress →Study challenges long-held fears about overactive bladder drugs and dementia
New research published in JAMA Network Open finds anticholinergic medications, commonly prescribed for overactive bladder (OAB), may not increase dementia risk after all compared to beta-3 agonists, the newer drug class that has been presumed to be safer for the brain.
Read at Medical Xpress →Engineered protein that cuts Alzheimer's-linked brain deposits opens potential therapeutic avenue
A KAIST-led research team has found that a protein involved in gene regulation can suppress the harmful aggregation of amyloid-beta, a peptide associated with Alzheimer's disease. The approach also reduced the toxicity of protein aggregates that had already formed.
Read at Medical Xpress →Cholesterol transport protein emerges as possible target for Parkinson's treatment
Parkinson's disease (PD) is a neurodegenerative condition that causes the progressive loss of dopamine-producing neurons in a brain region called the substantia nigra. Its characteristic symptoms include tremors, slowed movements, rigid muscles and difficulties with balance.
Read at Medical Xpress →Wireless neural chip tracks brain changes in real time after Alzheimer's drug administration
A joint research team led by KAIST has used a small, implantable neural chip to wirelessly monitor real-time changes in a neurotransmitter involved in memory and learning after an Alzheimer's drug has been administered. …
Read at Medical Xpress →Treatment revives old liver cells in lab study, may help prevent Alzheimer's and heart disease
The liver's job of clearing harmful substances from the body is so essential that the organ may have implications for addressing unexpected diseases, including Alzheimer's and heart disease. …
Read at Medical Xpress →Experimental treatment selectively reduces harmful protein in lab models of rare inherited brain disorder
Researchers from DZNE and the Hertie Institute for Clinical Brain Research (HIH) at the University of Tübingen, together with experts from Bonn, London and Portugal…
Read at Medical Xpress →Search for Alzheimer's drug unexpectedly finds possible biomarker
Researchers developed a drug for Alzheimer's disease and then discovered that the molecule already exists in human blood and is found at lower levels in cognitively impaired people. Now the authors are exploring the peptide as a biomarker as well as a treatment.
Read at Medical Xpress →Brain PET scans help select and monitor patients for new Alzheimer's drugs
Nuclear medicine is playing an increasingly important role in the diagnosis and treatment of Alzheimer's disease, helping clinicians visualize the biological changes associated with the condition and guide decisions about new therapies. …
Read at Medical Xpress →New drug-delivery method offers promise in fight against neurodegenerative diseases
For patients battling neurodegenerative diseases like ALS, Parkinson's, Alzheimer's and other dementias, delivering disease-fighting antibody drugs directly to the brain has proven to be a difficult task. …
Read at Medical Xpress → Archived copy (25 Oct 2026), Internet ArchiveWho gets Alzheimer's drugs? Race, vulnerability and health status shape access
The first disease-modifying drugs for Alzheimer's disease offer patients the ability to slow cognitive decline by targeting amyloid plaques in the brain. But a new study suggests that not all patients have the same opportunity to receive these treatments.
Drug combination that reduces oxygen levels in tissues improves Parkinson's symptoms in mice
In a new study, Broad Institute researchers report that two small-molecule chemicals that reduce oxygen delivery to cells improved symptoms of neurodegeneration in a mouse model of Parkinson's disease. …
Read at Medical Xpress →Starting Alzheimer's treatment earlier increases benefits to patients and society
New treatments that can slow the progression of Alzheimer's disease could provide significant lifetime benefits to patients and society, with even greater benefits when initiated earlier, according to new research from the USC Schaeffer Center for Health Policy & Economics.
Read at Medical Xpress → Archived copy (7 Oct 2026), Internet ArchiveClinical trial tests AI-assisted medication device for older adults with memory loss
Marianne Blake has lived in the same home for nearly half a century. She plays bridge regularly, drives to her hair appointments and, at 88 years old, enjoys her independence.
Read at Medical Xpress →Gene editing approach opens potential new route to Alzheimer's treatment
Dr. Kevin Kemp and his research team at the University of Bristol have converted the high-risk Alzheimer's gene APOE4 into the lower-risk APOE3 gene.
Read at Medical Xpress → Archived copy (29 Sep 2026), Internet ArchiveCan hormone replacement therapy prevent dementia? What the latest research tells us
A study has raised a question that many women would understandably want answered: Could hormone replacement therapy (HRT) protect against dementia? …
Why it matters: A study raised a key question about whether hormone replacement therapy (HRT) could help protect women against dementia.
Read at Medical Xpress →Blood proteins shift during Alzheimer's treatment and may help monitor the effects of the medication
Patients with early symptoms of Alzheimer's disease may be prescribed anti-amyloid therapy, which can help clear the sticky clumps of amyloid protein in the brain that characterize Alzheimer's. …
Why it matters: Shifts in blood proteins during Alzheimer's treatment may help monitor the effects of medication in patients receiving anti-amyloid therapy.
Seniors with dementia being prescribed dangerous mind-altering drugs, study says
Many seniors with dementia are being put at risk by brain-altering medications linked to falls, confusion and hospitalization, a new study says.
Why it matters: Many seniors with dementia are put at risk by brain-altering medications linked to falls, confusion, and hospitalization, according to a new study.
Read at Medical Xpress → Archived copy (17 Jan 2026), Internet ArchiveSafe, low-cost Alzheimer's drug demonstrates efficacy against sickle cell anemia
Memantine, a long-approved and cost-effective drug used to treat Alzheimer's disease, could also benefit patients with sickle cell anemia in the future. …
Why it matters: Memantine, a long-approved and cost-effective Alzheimer's drug, shows potential to benefit patients with sickle cell anemia in the future.
Read at Medical Xpress →New ALS treatment target identified: STAUFEN-1 protein reduction protects brain cells from death
University of Utah researchers at the Pulst-Scoles Laboratory have discovered that reducing levels of the STAUFEN-1 protein can prevent neuron death caused by DNA damage and p53 activation in neurodegenerative diseases.
Why it matters: Reducing STAUFEN-1 protein levels can prevent neuron death caused by DNA damage and p53 activation in neurodegenerative diseases like ALS.
Read at Medical Xpress →Key phospholipid points to potential treatment for vascular dementia
A possible new treatment for impaired brain blood flow and related dementias is on the horizon. Research by scientists at the University of Vermont Robert Larner…
Why it matters: Research by scientists at the University of Vermont Robert Larner points to a potential treatment for impaired brain blood flow and vascular dementia.
Read at Medical Xpress → Archived copy (3 Jan 2026), Internet ArchiveMiddle-aged brains show capacity for repair when treated with therapeutic intervention
Normal aging is characterized by deficits in the cognitive domains of learning, memory and executive function. Specifically, there are age-related changes in recall of information, speed of processing, visuospatial skills and cognitive flexibility. …
Why it matters: Normal aging brings cognitive deficits in learning, memory, and executive function, but middle-aged brains demonstrate a capacity for repair when treated with therapeutic intervention.
Read at Medical Xpress → Archived copy (29 Dec 2025), Internet ArchivePill form of semaglutide fails to slow Alzheimer's in large trial
A pill version of semaglutide, the ingredient in Ozempic and Wegovy, did not slow the progress of Alzheimer's disease, drugmaker Novo Nordisk announced on Nov. 24.
Why it matters: A pill form of semaglutide failed to slow Alzheimer's disease progression in a large trial, Novo Nordisk announced on Nov. 24.
Read at Medical Xpress → Archived copy (6 Jan 2026), Internet ArchiveNovel discovery reveals how brain protein OTULIN controls tau expression and could transform Alzheimer's treatment
Scientists have uncovered a surprising mechanism by which a brain enzyme called OTULIN controls the expression of tau, the protein that forms toxic tangles in Alzheimer's disease. …
Why it matters: Scientists uncovered a surprising mechanism by which the brain enzyme OTULIN controls tau expression, which could transform Alzheimer's treatment.
Read at Medical Xpress → Archived copy (25 Nov 2025), Internet ArchiveHow AI can create a virtual programmable human and revolutionize drug discovery
From idea, to lab, to clinic, to approval—it's a long and expensive process to bring a drug to market. It also rarely succeeds.
Why it matters: AI can create a virtual programmable human and revolutionize drug discovery, which is key because bringing a drug to market is a long, expensive process that rarely succeeds.
Read at Medical Xpress → Archived copy (17 Dec 2025), Internet ArchiveShingles vaccine most promising common drug to potentially prevent Alzheimer's
A new study has identified three existing medications that could be repurposed to treat or prevent Alzheimer's disease.
Why it matters: A new study identified three existing medications, including the shingles vaccine, that could be repurposed to treat or prevent Alzheimer's disease.
Read at Medical Xpress → Archived copy (19 Nov 2025), Internet ArchiveProtective microglia subtype offers potential therapeutic pathway in Alzheimer's disease
In Alzheimer's disease—the leading cause of dementia—microglia, the brain's immune defenders, can act as both protectors and aggressors, shaping how the disease progresses.
Read at Medical Xpress → Archived copy (15 Nov 2025), Internet ArchiveFollow new items in a feed reader: Atom feed.